| http://www.w3.org/ns/prov#value | - Lemtrada was a centerpiece of its $20-billion purchase of the biotech in 2011, and contingent payments valued at $3.8 billion, for such things as regulatory approval and the drug hitting specific sales targets, were tacked onto the takeover deal.
|
